RU2020123616A - Диагностика и лечение рака, связанного с раковыми стволовыми клетками - Google Patents
Диагностика и лечение рака, связанного с раковыми стволовыми клетками Download PDFInfo
- Publication number
- RU2020123616A RU2020123616A RU2020123616A RU2020123616A RU2020123616A RU 2020123616 A RU2020123616 A RU 2020123616A RU 2020123616 A RU2020123616 A RU 2020123616A RU 2020123616 A RU2020123616 A RU 2020123616A RU 2020123616 A RU2020123616 A RU 2020123616A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- antibody
- cldn6
- paragraphs
- stem cells
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 71
- 201000011510 cancer Diseases 0.000 title claims 70
- 210000000130 stem cell Anatomy 0.000 title claims 30
- 238000011282 treatment Methods 0.000 title claims 5
- 238000000034 method Methods 0.000 claims 68
- 102100038449 Claudin-6 Human genes 0.000 claims 40
- 101000882898 Homo sapiens Claudin-6 Proteins 0.000 claims 40
- 238000002512 chemotherapy Methods 0.000 claims 16
- 239000000523 sample Substances 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 15
- 239000000611 antibody drug conjugate Substances 0.000 claims 14
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 14
- 230000000771 oncological effect Effects 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 230000001093 anti-cancer Effects 0.000 claims 6
- 238000011319 anticancer therapy Methods 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 238000001959 radiotherapy Methods 0.000 claims 6
- 231100000331 toxic Toxicity 0.000 claims 6
- 230000002588 toxic effect Effects 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 238000003018 immunoassay Methods 0.000 claims 5
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 4
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 4
- 229940125644 antibody drug Drugs 0.000 claims 4
- 108010044540 auristatin Proteins 0.000 claims 4
- 238000009739 binding Methods 0.000 claims 4
- 239000000562 conjugate Substances 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 4
- 108010059074 monomethylauristatin F Proteins 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 229940127554 medical product Drugs 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 claims 2
- 102000005600 Cathepsins Human genes 0.000 claims 2
- 108010084457 Cathepsins Proteins 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 210000000170 cell membrane Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
- 230000009089 cytolysis Effects 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 238000011275 oncology therapy Methods 0.000 claims 2
- 238000001556 precipitation Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 238000003127 radioimmunoassay Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 230000004520 agglutination Effects 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 239000013060 biological fluid Substances 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 230000000951 immunodiffusion Effects 0.000 claims 1
- 238000010166 immunofluorescence Methods 0.000 claims 1
- 230000002055 immunohistochemical effect Effects 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 230000006882 induction of apoptosis Effects 0.000 claims 1
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 239000002777 nucleoside Chemical class 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000000941 radioactive substance Substances 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2013/002272 | 2013-07-31 | ||
| PCT/EP2013/002272 WO2015014376A1 (en) | 2013-07-31 | 2013-07-31 | Diagnosis and therapy of cancer involving cancer stem cells |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016107005A Division RU2749867C2 (ru) | 2013-07-31 | 2014-07-30 | Диагностика и лечение рака, связанного с раковыми стволовыми клетками |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020123616A true RU2020123616A (ru) | 2020-09-10 |
Family
ID=48914215
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020123616A RU2020123616A (ru) | 2013-07-31 | 2014-07-30 | Диагностика и лечение рака, связанного с раковыми стволовыми клетками |
| RU2016107005A RU2749867C2 (ru) | 2013-07-31 | 2014-07-30 | Диагностика и лечение рака, связанного с раковыми стволовыми клетками |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016107005A RU2749867C2 (ru) | 2013-07-31 | 2014-07-30 | Диагностика и лечение рака, связанного с раковыми стволовыми клетками |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10604568B2 (enExample) |
| JP (5) | JP2016533738A (enExample) |
| KR (4) | KR102483410B1 (enExample) |
| CN (3) | CN105407922B (enExample) |
| AR (1) | AR097178A1 (enExample) |
| AU (3) | AU2014298505B2 (enExample) |
| BR (1) | BR112016002000A2 (enExample) |
| CA (1) | CA2919570A1 (enExample) |
| DK (1) | DK3027208T3 (enExample) |
| ES (2) | ES2807181T3 (enExample) |
| HU (1) | HUE050622T2 (enExample) |
| IL (4) | IL308523B2 (enExample) |
| MX (2) | MX385872B (enExample) |
| NZ (1) | NZ716473A (enExample) |
| PT (1) | PT3027208T (enExample) |
| RU (2) | RU2020123616A (enExample) |
| SG (2) | SG11201600722PA (enExample) |
| UA (1) | UA123428C2 (enExample) |
| WO (2) | WO2015014376A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2750985C (en) | 2009-02-20 | 2022-07-19 | Ganymed Pharmaceuticals Ag | Methods and compositions for diagnosis and treatment of cancer |
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| NZ724296A (en) | 2011-05-13 | 2020-05-29 | Ganymed Pharmaceuticals Ag | Antibodies for treatment of cancer expressing claudin 6 |
| KR101935088B1 (ko) | 2012-08-24 | 2019-01-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
| WO2015014376A1 (en) * | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| US10053511B2 (en) | 2013-11-06 | 2018-08-21 | Abbvie Stemcentrx Llc | Anti-claudin antibodies and methods of use |
| MX372621B (es) * | 2015-03-31 | 2020-05-07 | Mitsubishi Power Ltd | Caldera y quemador de combustión |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| US20180371550A1 (en) * | 2015-07-08 | 2018-12-27 | Children's Hospital Medical Center | Loss of transcriptional fidelity leads to immunotherapy resistance in cancers |
| IL299099B2 (en) | 2016-06-27 | 2025-07-01 | Univ California | Cancer treatment combinations |
| CA3029902A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| WO2018232349A1 (en) * | 2017-06-15 | 2018-12-20 | Development Center For Biotechnology | Antibody-drug conjugates containing anti-globo h antibodies and uses thereof |
| WO2019048040A1 (en) * | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
| JP7416686B2 (ja) * | 2017-09-13 | 2024-01-17 | バイオエヌテック エスエー | 体細胞を再プログラムするためのｒｎａレプリコン |
| NO20210351A1 (en) * | 2017-09-18 | 2021-03-18 | Univ California | Claudin6 antibodies and methods of treating cancer |
| CN117003875A (zh) | 2017-09-29 | 2023-11-07 | 第一三共株式会社 | 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用 |
| US20210317453A1 (en) * | 2018-08-13 | 2021-10-14 | Cancerstem Tech Inc. | Cancer stem cell marker and cancer stem cell targeting drug |
| AU2020223293A1 (en) | 2019-02-15 | 2021-08-19 | Integral Molecular, Inc. | Claudin 6 antibodies and uses thereof |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| SI3941946T1 (sl) * | 2019-03-20 | 2025-09-30 | The Regents Of The University Of California | Protitelesa proti klavdinu-6 in konjugati zdravil |
| MX2022000111A (es) * | 2019-07-10 | 2022-02-10 | Chugai Pharmaceutical Co Ltd | Moleculas de union a claudina-6 y usos de las mismas. |
| CN111087465B (zh) * | 2019-12-24 | 2020-12-08 | 广州医科大学 | 一种针对密蛋白6的抗体偶联药物及应用 |
| CN113832226B (zh) * | 2020-06-24 | 2023-06-30 | 广州医科大学附属第五医院 | 研究gnl3与肝癌发展的相关性的方法及gnl3作为肝肿瘤干细胞、肝癌标志物的用途 |
| JP2024511277A (ja) | 2021-02-19 | 2024-03-13 | メビオン・メディカル・システムズ・インコーポレーテッド | 粒子線治療システムのためのガントリー |
| KR20250114330A (ko) | 2022-11-30 | 2025-07-29 | 인테그럴 몰큘러 인코포레이티드 | 클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식 |
| WO2024165057A1 (en) * | 2023-02-07 | 2024-08-15 | LaNova Medicines Limited | Antibodies and antibody-drug conjugates targeting claudin 6 |
| US12403202B2 (en) | 2023-05-25 | 2025-09-02 | The Regents Of The University Of California | Dosage of claudin-6 conjugates for cancer treatment |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
| US5830755A (en) | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO2000012708A2 (en) | 1998-09-01 | 2000-03-09 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
| US5928631A (en) | 1997-06-09 | 1999-07-27 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins |
| US20020127584A1 (en) | 1997-09-18 | 2002-09-12 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US5932445A (en) | 1997-11-07 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Signal peptide-containing proteins |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU773028B2 (en) | 1998-11-03 | 2004-05-13 | Adherex Technologies Inc. | Compounds and methods for modulating claudin-mediated functions |
| JP2002532083A (ja) | 1998-12-17 | 2002-10-02 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ４７個のヒト分泌タンパク質 |
| WO2000050588A2 (en) | 1999-02-22 | 2000-08-31 | Incyte Pharmaceuticals, Inc. | Genes associated with diseases of the colon |
| PT1185648E (pt) | 1999-06-22 | 2007-06-29 | Genentech Inc | Métodos e composições para a inibição do crescimento de células neoplásicas. |
| AU2883700A (en) | 1999-06-23 | 2001-01-09 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1514933A1 (en) | 1999-07-08 | 2005-03-16 | Research Association for Biotechnology | Secretory protein or membrane protein |
| EP1242443A4 (en) | 1999-12-23 | 2005-06-22 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
| WO2001051513A2 (en) | 2000-01-14 | 2001-07-19 | Corixa Corporation | Ovarian tumor-associated sequences |
| DK2796553T3 (da) | 2000-03-30 | 2019-09-30 | Whitehead Inst Biomedical Res | Rna-sekvensspecifikke formidlere af rna-interferens |
| AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1309620A2 (en) | 2000-06-23 | 2003-05-14 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| EP1354040A2 (en) | 2000-07-20 | 2003-10-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2004516013A (ja) | 2000-07-20 | 2004-06-03 | ジェネンテック・インコーポレーテッド | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
| US7351802B2 (en) | 2000-07-25 | 2008-04-01 | Genentech, Inc. | PRO19672 antibodies |
| EA007958B1 (ru) | 2000-08-03 | 2007-02-27 | Терапеутик Хьюман Поликлоналз Инк. | ТРАНСГЕННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ГУМАНИЗИРОВАННЫЙ ЛОКУС Ig, И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ ТРАНСГЕННЫХ ЖИВОТНЫХ |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP2000148A1 (en) | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of prostate cancer |
| CA2379661A1 (en) | 2002-03-28 | 2003-09-28 | Kursad Turksen | Paracellular drug delivery system |
| KR20040101502A (ko) | 2002-04-16 | 2004-12-02 | 제넨테크, 인크. | 종양의 진단 및 치료 방법 및 이를 위한 조성물 |
| US20070207142A1 (en) * | 2002-05-08 | 2007-09-06 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| JP2006516089A (ja) | 2002-10-02 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
| ES2744275T3 (es) | 2002-10-17 | 2020-02-24 | Genmab As | Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple |
| EP1578996A4 (en) | 2002-10-18 | 2007-12-19 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS |
| AT500651B9 (de) | 2003-05-27 | 2010-04-15 | Altropus Gmbh | Aktiv immunisierender antikörper |
| CA2527621A1 (en) | 2003-05-30 | 2004-12-23 | Centocor, Inc. | Method of inhibiting tumor growth with anti-tissue factor antibodies |
| KR20060031809A (ko) * | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| US20080305493A1 (en) | 2004-03-08 | 2008-12-11 | Avalon Pharmaceuticals | Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods |
| US7431927B2 (en) | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| DE102005025041A1 (de) | 2005-05-30 | 2006-12-07 | Bell Flavors & Fragrances Duft Und Aroma Gmbh | Mittel zur Anwendung in Spülmaschinen sowie Vorrichtung für dessen dosierte Einbringung während der Spül- und Trocknungsphasen |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| PL2089425T3 (pl) * | 2006-11-10 | 2012-02-29 | Covx Tech Ireland Limited | Związki przeciwangiogenne |
| WO2008114733A1 (ja) | 2007-03-16 | 2008-09-25 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-4抗体 |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2009025759A1 (en) | 2007-08-17 | 2009-02-26 | Progenics Pharmaceuticals (Nevada), Inc. | Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof |
| WO2009028663A1 (ja) | 2007-08-30 | 2009-03-05 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-3抗体 |
| EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| SG187457A1 (en) | 2008-01-11 | 2013-02-28 | Univ Tokyo | Anti-cldn6 antibody |
| WO2009120905A2 (en) * | 2008-03-26 | 2009-10-01 | Cellerant Therapeutics, Inc. | Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
| US20090258096A1 (en) | 2008-04-11 | 2009-10-15 | Bionovo, Inc. | Anticancer Methods Employing Extracts of Gleditsia sinensis Lam |
| EP2352764B1 (en) | 2008-10-14 | 2018-03-28 | Ablynx N.V. | AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY |
| DE102009026973A1 (de) | 2008-12-18 | 2010-07-01 | Robert Bosch Gmbh | Bremsanlage für ein Kraftfahrzeug und Verfahren zu ihrer Steuerung |
| JP2010178650A (ja) * | 2009-02-04 | 2010-08-19 | Univ Of Tokyo | 固形癌の再発予測のための試験方法および再発予防剤 |
| CA2750985C (en) | 2009-02-20 | 2022-07-19 | Ganymed Pharmaceuticals Ag | Methods and compositions for diagnosis and treatment of cancer |
| EP2221063A1 (en) | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
| NZ716587A (en) * | 2009-11-11 | 2017-10-27 | Ganymed Pharmaceuticals Ag | Antibodies specific for claudin 6 (cldn6) |
| EP2322555A1 (en) * | 2009-11-11 | 2011-05-18 | Ganymed Pharmaceuticals AG | Antibodies specific for claudin 6 (CLDN6) |
| WO2011105551A1 (ja) * | 2010-02-26 | 2011-09-01 | 国立大学法人大阪大学 | 癌幹細胞の検出方法、及び癌の治療剤または再発予防剤 |
| JP2011213612A (ja) * | 2010-03-31 | 2011-10-27 | Kyowa Hakko Kirin Co Ltd | 癌幹細胞及び／または癌前駆細胞の減少剤 |
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| NZ724296A (en) * | 2011-05-13 | 2020-05-29 | Ganymed Pharmaceuticals Ag | Antibodies for treatment of cancer expressing claudin 6 |
| EP2749641B1 (en) * | 2011-09-07 | 2021-06-02 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell isolation |
| EP2605017A1 (de) | 2011-12-16 | 2013-06-19 | Protagen AG | Markersequenzen für gynäkologisches Malignom und deren Verwendung |
| KR101242726B1 (ko) | 2012-01-26 | 2013-03-13 | 한국과학기술원 | 종양줄기세포 특성 암의 진단 및 치료제 |
| WO2014015148A1 (en) | 2012-07-19 | 2014-01-23 | Amgen Inc. | Human btnl3 proteins, nucleic acids, and antibodies and uses thereof |
| WO2014075697A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| HK1209434A1 (en) * | 2012-11-13 | 2016-04-01 | Astellas Pharma Inc. | Agents for treatment of claudin expressing cancer diseases |
| EA201591293A1 (ru) * | 2013-03-14 | 2016-02-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для доставки антител, кодируемых мрнк |
| WO2015014376A1 (en) * | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
-
2013
- 2013-07-31 WO PCT/EP2013/002272 patent/WO2015014376A1/en not_active Ceased
-
2014
- 2014-07-29 IL IL308523A patent/IL308523B2/en unknown
- 2014-07-30 KR KR1020217031149A patent/KR102483410B1/ko active Active
- 2014-07-30 CN CN201480042769.8A patent/CN105407922B/zh active Active
- 2014-07-30 IL IL243408A patent/IL243408B/en unknown
- 2014-07-30 AU AU2014298505A patent/AU2014298505B2/en active Active
- 2014-07-30 SG SG11201600722PA patent/SG11201600722PA/en unknown
- 2014-07-30 CA CA2919570A patent/CA2919570A1/en active Pending
- 2014-07-30 JP JP2016530504A patent/JP2016533738A/ja active Pending
- 2014-07-30 DK DK14750331.2T patent/DK3027208T3/da active
- 2014-07-30 KR KR1020247014359A patent/KR102867808B1/ko active Active
- 2014-07-30 ES ES14750331T patent/ES2807181T3/es active Active
- 2014-07-30 ES ES20180951T patent/ES3041948T3/es active Active
- 2014-07-30 RU RU2020123616A patent/RU2020123616A/ru unknown
- 2014-07-30 KR KR1020227045732A patent/KR102663127B1/ko active Active
- 2014-07-30 IL IL310824A patent/IL310824A/en unknown
- 2014-07-30 WO PCT/EP2014/066330 patent/WO2015014870A1/en not_active Ceased
- 2014-07-30 US US14/904,011 patent/US10604568B2/en active Active
- 2014-07-30 CN CN202110630292.7A patent/CN113252898A/zh active Pending
- 2014-07-30 HU HUE14750331A patent/HUE050622T2/hu unknown
- 2014-07-30 UA UAA201601865A patent/UA123428C2/uk unknown
- 2014-07-30 PT PT147503312T patent/PT3027208T/pt unknown
- 2014-07-30 MX MX2016001186A patent/MX385872B/es unknown
- 2014-07-30 BR BR112016002000A patent/BR112016002000A2/pt not_active Application Discontinuation
- 2014-07-30 KR KR1020167005323A patent/KR102308813B1/ko active Active
- 2014-07-30 IL IL293880A patent/IL293880B2/en unknown
- 2014-07-30 RU RU2016107005A patent/RU2749867C2/ru active
- 2014-07-30 CN CN202110621737.5A patent/CN113406327B/zh active Active
- 2014-07-30 SG SG10201800834RA patent/SG10201800834RA/en unknown
- 2014-07-30 NZ NZ716473A patent/NZ716473A/en unknown
- 2014-07-31 AR ARP140102879A patent/AR097178A1/es active IP Right Grant
-
2016
- 2016-01-27 MX MX2021010672A patent/MX2021010672A/es unknown
-
2019
- 2019-02-07 JP JP2019020349A patent/JP6865778B2/ja active Active
-
2020
- 2020-02-18 JP JP2020024949A patent/JP7136822B2/ja active Active
- 2020-02-19 US US16/795,468 patent/US11795218B2/en active Active
- 2020-02-24 AU AU2020201331A patent/AU2020201331B2/en active Active
-
2022
- 2022-07-19 AU AU2022206711A patent/AU2022206711B2/en active Active
- 2022-09-01 JP JP2022139001A patent/JP7611196B2/ja active Active
-
2023
- 2023-06-22 US US18/339,837 patent/US20240059772A1/en active Pending
-
2024
- 2024-10-04 JP JP2024174919A patent/JP2025011178A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020123616A (ru) | Диагностика и лечение рака, связанного с раковыми стволовыми клетками | |
| US20210000816A1 (en) | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer | |
| Hayes et al. | Antitumor activity of an anti‐CD 98 antibody | |
| JP2016520082A5 (enExample) | ||
| WO2019122337A1 (en) | Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule | |
| Hong et al. | Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts | |
| RU2019141270A (ru) | Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител | |
| AU2024201856A1 (en) | Combination therapy using a LIV1-ADC and a chemotherapeutic | |
| CN119656302A (zh) | 治疗主体中c1013g/cxcr4相关的华氏巨球蛋白血症的药物组合物、评估方法及药剂盒 | |
| Amini-Khoei et al. | Tropisetron suppresses colitis-associated cancer in a mouse model in the remission stage | |
| CA2732497C (en) | Use of opioids or opioid mimetics for the treatment of resistant cancer patients | |
| US20180057603A1 (en) | Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers | |
| Zheng et al. | Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin‑1 receptor | |
| Zhang et al. | CP41, a novel curcumin analogue, induces apoptosis in endometrial cancer cells by activating the H3F3A/proteasome-MAPK signaling pathway and enhancing oxidative stress | |
| Kievit et al. | Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial | |
| AU2014306322A1 (en) | Combination of IFN-gamma with anti-erbB antibody for the treatment of cancers | |
| EP4464337A1 (en) | Combined use of anti-trop-2 antibody-drug conjugate and other therapeutic agents | |
| WO2012020123A9 (en) | Neuropilin as a biomarker for bevacizumab combination therapies | |
| Jubran et al. | Mortalin peptides exert antitumor activities and act as adjuvants to antibody-mediated complement-dependent cytotoxicity | |
| US11446516B2 (en) | Methods of increasing response to cancer radiation therapy | |
| RU2842292C1 (ru) | Способы лечения рака посредством введения ингибитора pd-1 | |
| JP7357543B2 (ja) | がん細胞の抗がん治療に対する感受性を増大させる方法 | |
| AU2023331612A1 (en) | Drug conjugates of humanized anti pvr antibodies | |
| Popiel et al. | A first-in-class bispecific antibody CPL976 with a dual PD-L1/AXL mechanism of action that promotes common biological antitumor effects in in vitro and in vivo models. | |
| JP2023136704A (ja) | 癌の予防及び／又は治療薬 |